다운로드 Oncology Nursing Drug Handbook - v3.5.13

Patchwork, MCQ Abubakr (ASU), Jan Aushadhi Sugam (BPPI), Dexcom G6, iDentist Dental practice management, Medical PG, FMGE Preparation - PrepLadder만큼 좋은 애플리케이션가 꽤 있고 의료 장르의 위대한 애플리케이션 중 하나 인 Oncology Nursing Drug Handbook - v3.5.13도 있습니다.

Skyscape Medpresso Inc에서 개발 한 Oncology Nursing Drug Handbook - v3.5.13는 Android 버전이 Android 5.0+ 이상이어야합니다. 따라서 필요한 경우 휴대 전화를 업데이트해야합니다.

Oncology Nursing Drug Handbook - v3.5.13 최신 버전은 3.5.13, 출시일은 2020-06-25이며 크기는 8.4 MB입니다.

Google Play에서 1000 다운로드에 대한 통계를 확인할 수 있습니다. 원하는 경우 Android 기기에 개별적으로 다운로드하거나 설치된 앱을 업데이트 할 수 있습니다. 앱을 업데이트하면 최신 기능에 더 많이 액세스하고 보안을 강화할 수 있습니다. 응용 프로그램의 안정성.

모든 게임이나 앱이 모든 휴대 전화와 호환되는 것은 아니기 때문입니다.이 게임이나 애플리케이션은 기기에서 사용할 수 없습니다. Android OS 버전, 화면 해상도 또는 Google Play에서 액세스를 허용하는 국가에 따라 다릅니다. 따라서 APK4Share에서 다음 작업을 할 수 있습니다. APK 파일을 쉽게 다운로드 할 수 있으며 이러한 제한이 적용되지 않습니다.

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity